Patent Grant
11577060
Cerebrospinal fluid (CSF) is a generally clear, colorless fluid that is produced in the ventricles, specifically the choroid plexuses, in the brain. The choroid plexus produces approximately 500 milliliters of CSF daily to accommodate flushing or recycling of CSF to remove toxins and metabolites, which happens several times per day. From the choroid plexus, CSF flows slowly through a channel (canal) into the spinal column, and then into the body. CSF is found in the space between the pia mater and the arachnoid mater, known as the subarachnoid space. CSF is also found in and around the ventricular system in the brain, which is continuous with the central canal of the spinal cord. It may be desirable to remove, condition, and return CSF to treat various medical conditions. The present disclosure sets forth treatment modalities, methodologies, and therapies in this context.
The information included in this Background section of the specification, including any references cited herein and any description or discussion thereof, is included for technical reference purposes only and is not to be regarded subject matter by which the scope of the invention is to be bound.
In some embodiments, the performance of CSF-treatment systems may be improved by various treatments of CSF, including heating the CSF to a target temperature, cooling the CSF to a target temperature, increasing CSF flow rate, applying light treatment to the CSF, applying an osmotic gradient to lyse cells, separating cells via their dielectric properties, applying spiral and/or centrifugal separation, binding additives to target particles within the CSF, other treatment techniques, or combinations of these.
Disclosed embodiments generally relate to improved systems and methods for treating biologic fluids of a human or animal subject. In some embodiments, a filter, such as a tangential flow filter (TFF), may be used to separate cerebrospinal fluid (CSF) into permeate and retentate. The permeate may be returned to the subject. In some embodiments, the retentate may subjected to additional conditioning. For example, it may be filtered again, such as through one or more additional tangential flow filters or other methods of filtering. During operation of the system, various parameters may be modified, such as flow rate and pressure. Certain systems and methods described herein may be combined with other systems and methods for conditioning, removing, or otherwise processing biological materials, such as those discussed in U.S. Pat. No. 8,435,204. In some embodiments, treating the biologic fluids may include heating CSF to a target temperature, cooling CSF to a target temperature, applying light treatment to CSF, separating cells via their dielectric properties, applying spiral and/or centrifugal separation, introducing additives to the CSF, applying combinations thereof, or other techniques
In certain embodiments, the treatment system 102 is a device or combination of devices that is configured to filter, concentrate, dialyze, separate, or otherwise treat or condition the fluid, its contents, or both. In some embodiments, the treatment system 102 may treat the subject by modifying the fluid. For example, the treatment system 102 may treat a portion of the subject's spinal cord or brain by cooling the withdrawn fluid and returning the cooled fluid to cause local cooling. The treatment system 102 may include a tangential flow filtration system (for example, as shown and described in relation to
The intake 104 may be a port through which fluid enters the treatment system 102. The retentate outlet 106 may be an outlet through which retentate exits the treatment system 102. The permeate outlet 108 may be an outlet through which permeate exists the treatment system 102.
The intake 104, retentate outlet 106, and permeate outlet 108 may be any kind of ports through which material or fluid may flow. These components may be configured to be in fluid connection by tubing 114. The components 104, 106, 108, 114 may include various fittings to facilitate the connection, including but not limited to compression fittings, flare fittings, bite fittings, quick connection fittings, Luer-type fittings, threaded fittings, and other components configured to enable fluid or other connection between two or more components. In addition to fittings, the components 104, 106, 108, 114 also may include various elements to facilitate use of the system 100, including but not limited to various valves, flow regulators, adapters, converters, stopcocks, reducers, and other elements.
In certain embodiments, there may be one or more outlets, such as one or more permeate outlets 108 and/or retentate outlets 106. For example, the system 100 illustrated in
The vessel 110 may be a container for storing fluid. For example, fluid leaving the treatment system 102 may be deposited in the vessel 110. The fluid deposited in the vessel 110 may be held for storage, waste disposal, processing, testing, or other uses. The vessel 110 may also be a reservoir for subsequent treatment, for example, through the same treatment system 102 or a different treatment system 102. This fluid may or may not be combined with previously filtered fluid.
The treatment site 112 may contain a particular fluid to be treated. In some embodiments, the treatment site 112 may be an anatomical entity or location within a human or animal subject, such as a chamber or CSF-containing space or a blood vessel. The treatment site 112 may be the source of the fluid, the destination of the fluid, or both. For example, the system 100 may remove or receive a volume of fluid from the treatment site 112, perform treatment, and return a portion of the processed and/or treated fluid to the treatment site 112.
The various components of the system 100 may be connected through tubing 114. For instance, in certain embodiments, there may be a length of the tubing 114 placing the treatment site 112 in fluid connection with the intake 104. The permeate outlet 108 may be in fluid connection with the treatment site 112 via a length of the tubing 114. The retentate outlet 106 may be in fluid connection with the vessel 110 via a length of the tubing 114. The tubing 114 may be any kind of system for transporting or containing fluid. While the connections within the system 100 are shown as being direct, the connections need not be. The various portions of the system 100 may be connected through combinations of connections and various tubing 114. In certain embodiments, the tubing 114 and other portions of the system 100 may be filled with priming fluid (e.g., saline). Longer lengths of tubing 114 may correspondingly comprise a larger amount of priming fluid; however, in some embodiments, larger amounts of priming fluid may result in an undesirable amount of dilution of “natural” or endogenous fluid, such as CSF. Accordingly, in some embodiments, the tubing 114 may be selected to minimize the volume of priming fluid needed, while still having the system be practically useful (e.g., enough tubing to enable the system 100 to be used at a subject's bedside). Depending on the subject and the treatment site 112, the tolerance for removal or dilution of fluid may vary, and the system 100 may be scaled accordingly. For example, the parameters of the system 100 may be changed to scale to suit subjects ranging from a mouse to a human or larger mammals.
In some embodiments, the tubing 114 may have a port 124 configured to provide access to the fluid traveling within the tubing 114. As illustrated in
As a specific example, the some embodiments shown in
The catheter 204 may, but need not, also include ports to place one or more lumens in fluid connection with the fluid 144 of the treatment site 112. The catheter 204 may be generally configured to be flexible, navigable, and atraumatic. The catheter 204 may enable sensing of temperature, intracranial pressure, and/or other parameters. The size of the catheter 204 may be approximately greater than or equal to 6 French and approximately 20 cm to approximately 120 cm to enable attachment to remote tubing (e.g. the tubing 104), a console (e.g., the treatment unit 106), or other units; however, other sizes may be used. In some embodiments, the catheter size may be approximately 5 French. Other diameters and lengths may be used, as desired.
Although
The pump 222 may be any device for inducing fluid flow through one or more portions of the treatment system 102. In certain embodiments, the pump 222 may be a peristaltic pump, which may reduce the need for sterilization of complex pump components; however, other types of pumps may be used. The operation of the pump 222 may be controlled by modifying the operating parameters of the pump 222. This may enable the flow rate, pressure, and/or other parameters of the pump 222 to be changed. The pump 222 may also be used to withdraw the fluid from the treatment site 112.
The air trap 223 can be used to facilitate priming the treatment system 102 and can be used to remove air bubbles from the system 102 to improve accuracy of the sensor 224. The air trap 223 can include a hydrophobic air vent.
The sensor 224 may be a device for generating and/or receiving information, including but not limited to one or more of characteristics of the fluid withdrawn from the treatment site 112, before, after, and/or during filtration, including but not limited to temperature; pressure; the ratio of permeate volume to retentate volume; the fluid flow rate to and/or from the treatment site 112; the amount of contaminants or other materials in the fluid; the fluid flow return rate; the filter efficiency; filter status (for example, whether the filters are clogged or otherwise running inefficiently); and other parameters or characteristics. While the sensor 224 is shown within the treatment system 102, one or more sensors 224 may be located elsewhere in the system 100 and/or cooperate with other locations. The sensor 224 may convert the data into computer- and/or human-readable representations for processing. While a single sensor is shown within the system, it will be understood that there need not be only as single sensor. Any suitable number or arrangement of sensors may be used for taking one or more readings throughout the system.
In some embodiments, the sensor 224 may be selected to or optimized for use with flow rates of approximately 0 to approximately 1200 milliliters per hour, volumes of approximately 100 to approximately 125 cubic centimeters, and pressures of approximately 0 to approximately 20 mmHg. These measurement ranges may be encountered in the system, such as in the flow rate, volume, and pressure of CSF or a heat exchange fluid. In some embodiments, the flow sensor may be accurate within a range of between approximately 0 to approximately 2400 milliliters per hour, the pressure sensor may have an effective operating range of between approximately −50 mmHg and approximately 300 mmHg. In some embodiments, sensor 224 may have a response time of approximately 20 ms. In some embodiments, the sensor 224 may be a temperature sensor configured to have an accuracy of +/−0.5° C. between approximately 4° C. and approximately 70° C. Suitable sensors may include flow sensors provided by SENSIRION of Switzerland, pressure sensors by UTAH MEDICAL of Midvale, Utah, and temperature sensors by SCILOG of Madison, Wis.
The treatment unit 226 may be configured to treat fluid and may be one or more components of the treatment system 102. For example, in some embodiments, the treatment unit may be a device for separating a first portion of materials and/or fluid from a second portion of materials and/or fluid. The design and type of the treatment unit 226 may vary depending on the type of fluid and the desired treatment results. For example, the treatment unit 226 may include a tangential flow filter configured to separate the fluid into permeate and retentate (see, for example,
In some embodiments, the treatment unit 226 may include multiple different treatment components, including but not limited to filters, components configured to increase the performance of filters, units configured to increase the flow rate of the fluid within the treatment system 102, units configured to heat the fluid, units configured to cool the fluid, units configured to apply light treatment to the fluid, units configured to separate components of the fluid based on their dielectric properties, units configured to apply spiral separation, units configured to apply centrifugal separation, units configured to introduce additives to the fluid, units configured to target particular components of the fluid, other components, and/or combinations thereof. Some embodiments may be configured to mechanically vibrate filters in order to reduce filter clogging, improve flow, and improve reliability. Some embodiments may include an inline air trap. The inclusion of an air trap may increase performance by, for example, removing air bubbles that may otherwise be detrimental to the system by causing erroneous sensor readings and filter airlocks.
The processing unit 228 may be a device configured to control the operation of the treatment system 102, for example by sending signals to the pump 222, sensor 224, and/or treatment unit 226. In some embodiments, the signals are sent in response to receiving input from the interface 210. In certain embodiments, the processing unit 228 may process information, such as data received from the sensor 224 and/or the interface 210 and make decisions based on the information. In certain embodiments, the processing unit 228 may itself make decisions based on the information. For example, the processing unit 228 may include a processor and memory for running instructions configured to receive input, make decisions, and provide output.
The interface 230 may be a device or system of devices configured to receive input and/or provide output. In certain embodiments, the interface 230 is a keyboard, touchpad, subject monitoring device, and/or other device configured to receive input. For example, a healthcare professional may use the interface 230 to start or stop the system 100 and to modify system parameters, such as the absolute duration of the procedure, pump speed, and other parameters. The interface 230 may also include a display, speaker, or other device for sending user-detectable signals. In some embodiments, the interface 230 may comprise a network interface configured to send communications to other devices. For example, the interface 230 may enable the treatment system 102 to communicate with other treatment systems, flow control devices, a server, and/or other devices.
As a specific example, the fluid 262 may be CSF having particular desirable components 252. The CSF may also contain contaminants 254, such as blood cells, blood cell fragments, hemolysis components, neutrophils, eosinophils, inflammatory cells, proteins, misfolded proteins, cytokines, bacteria, fungi, viruses, small and large molecules, oligomers (such as AP oligomers, tau oligomers, α-synuclein oligomers, and Huntingtin oligomers), antibodies (such as anti-myelin antibodies), enzymes, mutated enzymes (such as mutations to SOD1), and/or other substances. The contaminants 254 may, but need not, include materials or matter that are present in CSF normally (e.g. a cytokine that is present in CSF normally but is present in an elevated or otherwise undesirable amount). One or more of the contaminants 254 may be associated with or suspected to be associated with one or more diseases or conditions. For example, the contaminants 254 may be associated with one or more of Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, for instance, as described in U.S. application Ser. No. 13/801,215, which was previously incorporated by reference. The treatment unit 226 may be used to separate the contaminants 254 from the fluid and/or desirable components 252 of the CSF. For instance, a membrane 258 may be sized or otherwise configured to allow CSF to flow through the membrane 258 while substantially preventing contaminants 254 from passing through the membrane 258.
While the method is described as being performed on a particular volume of fluid, the system may operate on a continuous flow of fluid. That is, the system 100 need not necessarily withdraw a volume of fluid, wait for the volume to be processed and returned, and then withdraw another volume of fluid. The method may follow a continuous process. Similarly, while
The method 400 may begin at start 402. This step 402 may include activating one or more components of the system 100. This step 402 may also include or follow various preparation steps. Such steps may include installing treatment components, selecting and preparing the treatment site 112, installing tubing 114, calibrating components, priming components of the system 100, and other steps.
The installing treatment components step may include selecting particular treatment components based on desired outcomes, the particular treatment site 112, fluid, or other considerations. For example, if the method 400 is being used on a subject suffering from a cerebral vasospasm, the goal of the procedure may be to filter blood breakdown products from the subject's CSF. This would make the treatment site 112 a lumen carrying CSF, the fluid. As such, particular treatment components would be selected to filter the blood components from the CSF. For example, a membrane 258 with apertures sized to substantially prevent the flow of blood components, while large enough to substantially allow the entry of CSF as permeate, may be used.
As another example, if the method 400 is being used on a subject suffering from or suspected to be suffering from cyptococcal meningitis, the goal of the procedure may be to remove or inactivate Cryptococcus neoformans fungi that may be within the subject's CSF. The treatment site 112 may then be a lumen carrying CSF and treatment components may be selected to heat the CSF to inactivate the fungi and then filter the fungi from the CSF.
The selecting and preparing the treatment site 112 step may include choosing a particular treatment site 112. For example, a healthcare professional may select an individual who may benefit from having treatment performed on a bodily fluid and identify a reservoir containing the fluid. This may include, as described above, a subject suffering from a cerebral vasospasm. Preparing the treatment site 112 may include identifying an anatomical location for a procedure to access the treatment site 112 (for example, in a spinal portion 200, as shown in
Installing tubing 114 may include connecting various components of the system 100. For example, retentate outlet 106 may be connected to flow regulator 118. This step may also include installing tubing 114 to withdraw fluid from and return fluid to the treatment site 112. This step may include inserting a multi-lumen catheter into an anatomical location to place the treatment site 112 in fluid connection with the system 100 to enable fluid to be drawn into the intake 104 and returned to the treatment site 112.
Calibrating components may include setting initial parameters for the use of the system 100. This step may include establishing an initial flow rate, an initial pressure, and other initial parameters or system settings. The initial parameters may be based on observed or predicted clinical measures, including but not limited to an estimated amount of fluid in the treatment site 112, the health of the subject, the predicted ratio of retentate to permeate, and other factors.
Priming the system 100 may include adding a priming solution to one or more of the components of the system 100. Depending on the configuration of the system 100, priming may be necessary for one or more components to function effectively. Depending on the treatment site 112, fluid, and the subject, priming may be necessary to assure comfort or good health. In certain applications, the system 100 may be primed to enable the return of a volume of fluid while simultaneously withdrawing a volume of fluid. This may be especially useful for applications where the treatment site 112 has a relatively small volume of fluid (e.g., during filtration of CSF) or is otherwise sensitive to relative changes in volume. Depending on the type of filtration being used, the length of the procedure, and other factors, priming fluid may be added during the filtration procedure to make up for fluid lost during the procedure
At step 404, a volume of fluid is withdrawn from the treatment site 112. In certain circumstances, the fluid may be withdrawn using a pump or device located within the system 100. For example, the pump may be a component of one or more of the flow regulators 118; the treatment system 102 (such as pump 222); and/or the combiner 116. The pump may be used to withdraw a volume of fluid from the treatment site 112.
In some embodiments, the rate at which the fluid is withdrawn from the treatment site 112 is between approximately 0.01 mL/min and approximately 100 mL/min, between approximately 0.04 mL/min and approximately 30 mL/min, between approximately 0.1 mL/min and approximately 10 mL/min, or in other ranges. However, the amount withdrawn may be higher or lower depending on the application. The amount may vary depending on various factors including but not limited to the type of fluid being withdrawn, the viscosity of the fluid, the amount of fluid in the treatment site 112, and other factors. The viscosity of the fluid may vary over time, and depending on the particular subject. For example, the viscosity of CSF may be different in a subject with meningitis than a subject with typical CSF. Once the fluid is withdrawn from the treatment site 112, the fluid may pass through the tubing 114 and into the treatment system 102 via intake 104.
At step 406, the volume of fluid is treated. This may include the steps of passing the fluid through the treatment unit 226 of the treatment system 102. While the fluid passes through the treatment unit 226, it may pass through multiple different components to treat the fluid. For example, the fluid may be heat treated using a heating unit and then filtered using a filtration unit. As another example, the fluid may pass through various filtration components including but not limited to tangential flow filtration, microfiltration, ultrafiltration, nanofiltration, dead-end filters, depth filters, and other filtration devices or mechanisms.
The treatment process may result in the separation of the fluid into a retentate flow and a permeate flow. The permeate flow may leave the treatment system 102 through a permeate outlet 108 and the retentate may leave the treatment system 102 through a retentate outlet 106. Depending on the configuration of the filters and the goals of the method 400, in some implementations, the permeate may be the fluid to be returned to the treatment site 112. In other implementations, the retentate may be returned to the treatment site 112. The retentate may be a fluid that contains contaminants or is otherwise in a condition undesirable for returning to the treatment site 112.
In certain embodiments the retentate may be successively or progressively treated, such as by being treated again through another treatment process or by being treated again through the same treatment system 102 by being redirected through it. For example, in some embodiments, the retentate may be passed through a flow regulator and into treatment system 102 for additional filtration. The permeate may flow from the permeate outlet 108 to a combiner for return to the treatment site 112. The second retentate may be treated further. Once the fluid is sufficiently treated, the remaining retentate or contaminants may be passed through a flow regulator and into a vessel 110 for analysis, disposal, storage, or other use, or, alternatively, or in addition, the remaining retentate may be subjected to further processing, treatment, and/or filtration (any number of times), where the further treated fluid is, for example, directed to treatment site 112, either directly or in combination with other fluids.
At step 408, characteristics of the fluid and/or the system may be measured. Measuring characteristics may include intermittent or continuous sampling and/or monitoring of characteristics or parameters of interest. While this step 408 is shown as occurring after the treatment of the fluid 406, the step 408 may take place at any point during the process 400 where useful data may be gathered.
In certain embodiments, measuring characteristics may include measuring the characteristics of the fluid withdrawn from the treatment site 112 before, during, or after treatment. The characteristics measured may include the presence or amount of particular contaminants, proteins, compounds, markers, and other fluid components present. As another example, the ratio of permeate volume to retentate volume, the fluid flow rate from the treatment site 112, fluid temperature, fluid opacity or translucency or transparency, an absolute retentate flow rate, and the rate of fluid flow to the treatment site 112 also may be measured. The performance characteristics of the system 100 may also be measured. For example, the efficiency of the treatment unit 226, the status of the treatment unit 226 (for example, via the interface 210), and other markers of system 100 performance.
Data utilized by the system need not be limited to directly or actually measured data. Data may be inferred from actually measured data. For example, retentate flow rate may be determined using a difference between a pump rate and a permeate rate. This method would allow the system to measure a value that may be unmeasurable, difficult to measure, or inaccurate due to, for example, changing viscosity.
In certain embodiments, the characteristics measured may include information about a subject or input by a healthcare provider. For example, the system 100 may monitor the blood pressure, heart rate, stress, and other information of the subject. In addition to quantitative characteristics, qualitative measurements may be made as well. For instance, subject discomfort and other qualities may be measured. These and other data may be measured by the sensor 224 and/or be input into the system by an input device (for example, keyboard, touch screen, subject-monitoring device, and other devices for receiving input) operably coupled to the system 100.
At step 410, a volume of fluid is returned to the treatment site 112. In certain embodiments, the fluid is returned to the treatment site 112 as soon as fluid treatment has been completed. In certain embodiments, the flow rate of the fluid may be controlled. For example, a volume of fluid may be buffered at the combiner 116 or in another area of the system 100 for a time before being returned to the treatment site 112. Buffering may be used to smooth the return rate of the fluid, to allow time for the fluid to reach a particular temperature, to allow time for a particular additive to mix within the fluid, and for other reasons.
In certain embodiments, the rate and/or pressure at which the fluid is returned to the treatment site 112 is controlled so that the fluid is returned at such a rate or in such a manner as to maintain homeostasis within the treatment site 112. In certain embodiments, this may be accomplished by returning fluid at the same rate at which fluid is currently being withdrawn from the system. In certain embodiments, the fluid may be returned at substantially the same flow rate at which it was removed. The fluid volume removed from the system and returned to the system may not be equal. This may be the case when removing a significant quantity of contaminants from a treatment site. In certain embodiments, the difference may be made up through the addition of a secondary fluid or via the body's natural production.
In certain embodiments, a particular volume of additional fluid may be returned to the treatment site 112. The additional fluid may be fluid that was not withdrawn from the treatment site 112, previously withdrawn from the treatment site 112, withdrawn from a different treatment site, synthetically created, naturally created within the subject's body, or is otherwise different from the volume removed from the treatment site 112 in step 404. The return of additional fluid may be used to, for example, compensate for the volume of fluid that was filtered out, especially in circumstances where the treatment site 112 comprised only a small amount of fluid at the start 402.
In certain embodiments, one or more therapeutic agents may be added to the fluid prior to its return to the treatment site 112. The fluid may be treated or mixed with a particular pharmacological agent. For example, when the fluid is CSF, the agent may be configured to bypass the blood-brain barrier. The agents may include, but need not be limited to, antibiotics, nerve growth factor, anti-inflammatory agents, pain-relief agents, agents designed to be delivered using intrathecal means, agents designed to affect a particular condition (e.g., meningitis, Alzheimer's disease, depression, chronic pain, and other conditions), and other agents.
As a specific example, the treatment site 112 may be a CSF-containing space of a subject, such as the subarachnoid space or another space known or thought to contain CSF. The space may only have a total of approximately 125 ml of CSF, and if the level drops below a certain threshold (for example, approximately 85 ml), the subject may suffer undesirable side effects. If a particular large amount of the existing CSF comprises undesirable compounds, the volume of permeate may be small enough to cause the fluid levels in the treatment site 112 to drop below the threshold. Consequently, the system 100 may return a volume of additional fluid (for example, artificial CSF or other suitable fluid) to adjust for the difference between the amount of withdrawn CSF being returned and the amount needed to be returned to maintain the volume of the treatment site 112 above the threshold amount.
In certain embodiments, the withdrawal and return of the fluid may occur in a pulsed manner. For example, the system 100 may withdraw a particular volume and then cease withdrawing additional fluid. The withdrawn volume is treated and buffered (for example, at a combiner). An amount of the treated fluid from the buffer may be returned to the treatment site 112 at about the same rate and/or for the about same total volume as a next volume is withdrawn from the treatment site 112. This process may allow the system to maintain treatment site 112 volume levels relatively consistent and may be useful in circumstances where the processing time (for example, the time between the fluid being withdrawn from and returned to the treatment site 112) is long.
At step 412, a determination is made. The determination may be made by, for example, a healthcare professional, a processor system, or a combination thereof. For example, the healthcare professional may analyze the measured characteristics and come to a conclusion. As another example, the processing unit 208 may analyze the measured characteristics using an algorithm or through other mechanisms. The determination may be based on the measured parameters, a timer, a schedule, or other mechanisms. The determination may be used to change the parameters of the system 100, may change over time, and may address particular measured characteristics.
For example, a determination may be made regarding the flow rate at which the fluid is being withdrawn and/or returned to the treatment site 112. For example, it may be desirable to maintain substantially the same withdrawal and return rate of the fluid. Specifically, if more fluid is being withdrawn from the treatment site 112 than is being returned, then the volume of fluid in the treatment site 112 may be decreasing overall. This may be undesirable because for certain fluids and certain treatment sites 112, if the volume of the treatment site 112 passes a particular threshold, undesirable side effects may occur. For instance, where the fluid being withdrawn is CSF, the flow rate may be such that the volume of CSF removed from a human subject does not exceed about between approximately 5 mL and approximately 20 mL over the course of one hour. That is, the volume of fluid does not decrease more than approximately 5 mL to approximately 20 mL from its original starting volume in a one hour period of time. In certain embodiments, it may be desirable to maintain an absolute retentate flow rate within a certain range of acceptable retentate flow rates. In certain embodiments, the threshold may be between approximately 0.10 mL/min and approximately 0.30 mL/min. In certain embodiments, the threshold may be approximately 0.16 mL/min. In certain embodiments, the threshold may be between approximately 0.2 mL/min and approximately 0.25 mL/min; however, other values may be desirable in certain circumstances. In certain embodiments, a pump may be running at approximately 1.0 mL/min and the retentate flow rate is approximately 0.25 mL/min, the permeate flow rate is approximately 0.75 mL/min, which is about a 3:1 ratio. However, if the pump speed were increased to approximately 2.0 mL/min, the retentate flow rate may be held at approximately 0.25 mL/min, which leaves the permeate flow rate as approximately 1.75 mL/min, or about a 7:1 ratio. By maintaining the retentate flow rate within the threshold, the system may be considering functioning as intended, despite the change in ratios.
Based on the measured characteristics, it may be determined that the best way to address the disparity in the withdrawal and return rates may be to decrease the flow rate to reduce the overall volume of fluid lost from the system. This may mean that, although there is a net loss of fluid from the treatment site 112, the loss is occurring at a slower rate. The rate may be sufficiently slow that, for example, that the subject's body produces sufficient fluid to make up for the loss.
For example, at the beginning of the filtration process 400, the fluid may contain large amounts of contaminants, resulting in a comparatively large amount of material being filtered out and a comparatively small amount of the fluid being returned (for example, permeate). As the filtration or treatment process continues, the amount of fluid being treated may decrease because the contaminants have already been filtered out (for example, retentate). In this scenario, a determination may be made to begin the process at a relatively low flow rate and then increase it as the volume of the fluid being filtered out decreases. In addition, the determination may include altering the flow and/or pressure within the treatment unit 226 to achieve particular filtering results.
As another example, the measured characteristics may be a subject's expressed discomfort. Withdrawing CSF from a CSF-containing space of a subject may cause symptoms of overdrainage, such as spinal headache. Symptoms of overdrainage may be able to be avoided or otherwise addressed by not withdrawing more than a threshold amount of CSF. However, the particular threshold may vary from subject to subject. As such, a predicted threshold may be different from an actual threshold and the subject may experience symptoms sooner than expected. In response to the subject expressing feelings of discomfort, the healthcare professional may determine that the parameters of the process may need to be changed.
In some embodiments, a system may predict the occurrence of a spinal headache or a hemorrhage based on the amount of CSF removed from the subject and/or the subject's intracranial pressure. The system may be configured to modify treatment parameters responsive to detecting that a threshold amount of CSF was removed or a threshold intracranial pressure was reached. For example, the threshold amount may be an amount of CSF removed, an amount of CSF removed over a period of time, or an intracranial pressure predicted to induce spinal headache. In some embodiments, the threshold amount of CSF removed or the threshold amount of CSF removed over a period of time, may be within about 100% to about 50%, about 95%, about 90%, about 85%, or about 80% of the amount predicted to cause a spinal headache. In some embodiments, the threshold amount may be less than about 300% to about 100%, about 150%, about 125%, about 110%, about 105%, or about 100% of the amount of intracranial pressure predicted to cause a spinal headache. In some embodiments, the predicted volume of removed CSF (without replacement) that is sufficient to induce a spinal headache is an amount greater than 15 milliliters per hour.
In certain embodiments, at step 412, the processing unit 228 and/or a healthcare professional may determine that the process should be completed. At this point, the flow diagram moves to end step 416. In certain other embodiments, at step 412, the processing unit 228 and/or a healthcare professional may determine that the process should continue substantially unchanged. Upon that determination, the flow diagram may return to step 404. In still other embodiments, at step 412, the processing unit 228 and/or a healthcare professional may determine that the one or more parameters of the process should be changed. Upon that determination, the flow diagram may move to step 414.
At step 414, one or more parameters of the system 100 are changed in response to a determination made in step 412. The parameters to be changed may include inflow rate, outflow rate, buffer size, and other parameters. Such parameters may be changed via, for example, the processing unit 206 sending a signal to the pump 222 or other component of the system to modify the parameters. In certain embodiments, the parameters may be manually changed through input received at the input 208. This may include parameters entered by a healthcare professional. In certain embodiments, parameters may be updated based on the difference between the withdrawal volume and the returned volume (e.g., a waste rate).
In certain embodiments, the updating parameters step 414 may include changing the flow direction of the fluid. For example, a system may include a plurality of treatment systems, which the fluid may be directed to by the manipulation of a valve or other mechanisms for changing fluid flow direction. Step 414 may include changing the fluid flow from one treatment system to a different treatment system. This may be in response to determining that a second treatment system is more suited for particular treatments than a first treatment system.
In certain embodiments, the updating parameters step 414 may include modifying the positioning of the tubing at the treatment site 112. For example, one or more inflow or outflow tubes 114 may become clogged or otherwise be operating at a reduced capacity. In response, the tubing 114 may be adjusted or otherwise modified to address the reduced capacity issue. The healthcare professional may be alerted to the issue by a light, alarm or other indicia.
In certain embodiments, the updating parameters step 414 may include cleaning or otherwise modifying one or more components of the system 100, such as the treatment unit 226. This may be accomplished by, for example, changing back pressure and pump speed.
In certain embodiments, the updating parameters step 414 may include sensing characteristics of the system to determine whether the treatment unit 226 or other components of the system are experiencing clogging. The sensed characteristic may include reading an alert state of the treatment system or detecting an increase in filter pressure with no change to system flow rates or other parameters of the system. Responsive to determining that there may be a clog in the system 100, the flow rate through the retentate port of the filters may be increased. The increased flow rate may be the result of a user or the system opening a back pressure valve (e.g., a backpressure valve of the flow regulator 118). The opening of the valve may result in a surge of fluid through one or more retentate ports of one or more filters into a waste collection area (e.g., vessel 110). The surge of fluid may result in the flow returning to the treatment site 112 reducing to zero or even a negative rate. Thus, the operator or system controlling the flow rate may take into account the volume of fluid lost and the possible effects on the patient as a result of this filter clearance mechanism.
At step 416, the process comes to an end. After the process is completed, various wind-up steps may be performed, including but not limited to, applying a bandage to the subject, disassembling one or more components of the system 100, analyzing an amount of the withdrawn fluid, analyzing the retentate, and other steps.
Increasing the Performance of Filtration Systems
In some embodiments, the performance of a filtration system, such as tangential flow filtration systems, may be improved by heating the CSF to a target temperature, cooling the CSF to a target temperature, increasing CSF flow rate, applying light treatment to the CSF, separating cells via their dielectric properties, applying spiral and/or centrifugal separation, binding additives to target particles, applying combinations thereof, or other techniques.
Heating or Cooling CSF to a Target Temperature
In some embodiments, heating or cooling CSF to a target temperature may improve performance of a filtration system and provide other beneficial results. For example, heating or cooling CSF to a target temperature may affect microorganisms or other components of CSF. In particular, heating or cooling the CSF may inhibit microorganisms within the CSF. Inhibiting microorganisms may include impairing the ability of the microorganism to reproduce, preventing the microorganism from being able to reproduce, killing the microorganism, inactivating the microorganisms, attenuating the microorganisms, or otherwise decreasing the potential negative effects of the microorganism. For a system or process to inhibit microorganisms, it need not inhibit all microorganisms. For example, the system may inhibit about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, about 99.9%, about 99.99%, more than 99.99%, or another percentage of all microorganisms.
In addition to causing disease, microorganisms may reduce the effectiveness of CSF treatment systems. Reproducing fungi, viruses, and/or bacteria may clog a filter or other parts of the treatment system 100. Once a few microorganisms are on a filter, then they may continue to multiply and cover the entire filter. Further, once the microorganisms become lodged in a portion of the system, that portion may become a continuing reservoir of pathogens. One solution is to alter the temperature of the CSF to kill or inhibit the microorganisms.
The target microorganism may be a fungus such as Cryptococcus neoformans or Cryptococcus gattii, fungi responsible for cryptococcal meningitis. C. neoformans thrives in environments that are warm, such as 37° C., typical human body temperature. The ability of C. neoformans to thrive at this temperature makes it particularly deadly for people with immune compromised systems. However, C. neoformans has a maximum growth temperature of approximately 40° C. See, John R. Perfect, Cryptococcus neoformans: the Yeast that Likes It Hot, 6 FEMS Y
Like treating CSF with heat, cooling the CSF may impair the survivability of microorganisms. For example, cooling CSF may prevent or inhibit microorganisms from reproducing, thus reducing the likelihood of the microorganism clogging the treatment system 102 or otherwise reducing performance of the system 102. Some embodiments may be configured to cool CSF to a target temperature to precipitate out certain proteins and/or slow or stop reproduction of a target microorganism. The CSF may be cooled to a target temperature at which a target protein precipitates out of the solution. Proteins precipitate out of a solution once the protein reaches a certain temperature. In particular, proteins may be soluble in solution but become folded solid as they are cooled. The temperature at which the protein precipitates out may vary based on the target protein.
As the CSF is withdrawn from the target lumbar cistern treatment site 112, the CSF passes through an inlet lumen of the catheter 204 and enters the treatment system 102 through the intake 104. Next, a sensor 224 may read the pressure of the CSF as the CSF passes through a pump 222 and an air trap 223. The pressure of the CSF is taken again using a sensor 224 as the fluid moves through a temperature control unit 232.
The temperature control unit 232 may be a unit configured to cool or heat fluid as needed to reach a target temperature. The heating system may include various sensors and feedback loops to control the temperature. Various cooling techniques may be used, including but not limited to vapor-compression, thermoelectric cooling, radiator, cool bath, other techniques, or combinations thereof. Various heating techniques may be used, including but not limited to heating coils, warm baths, other techniques, or combinations thereof. While the temperature control unit 232 is illustrated as located within the treatment system 102, it may be located elsewhere within the system 100 as a whole. For example, the temperature control unit may be located external to the treatment system 102. In some embodiments, the temperature control unit 232 does not cool or warm the CSF directly and instead cools or warms a heat transfer fluid that is circulated to warm or cool the CSF. In other embodiments, the temperature control unit 232 cools or warms a filter of the treatment unit 226 itself.
The temperature control unit 232 may modify the temperature of the withdrawn CSF. For example, the temperature control unit 232 may cool or warm the CSF. After the CSF leaves the temperature control unit 232 (or is otherwise cooled), the CSF may be filtered using a filter of the treatment unit 226. In some embodiments, the CSF may be filtered before its temperature is modified. The treatment unit 226 may separate the CSF into permeate and retentate. The retentate may pass through the retentate outlet 106 and deposited in a vessel 110 for disposal or additional processing. The permeate may pass a pressure control sensor 224 and a flow rate sensor 224. Next, the permeate passes through the permeate outlet 108 and an outlet lumen of the catheter 204. The permeate then leaves the catheter 204 through the second port 208 and is deposited in the cervicothoracic junction treatment site 112.
The heating or cooling of the CSF may, but need not, be rapid. The system may be configured to alter the temperature of the CSF so the CSF reaches a target temperature by the time the CSF reaches a filter of the treatment unit 226. The target temperature may be a temperature above or below a temperature which target microorganisms (or a percentage thereof) reproduce and/or survive. For example, the temperature may be a temperature above which about 50%, about 75%, about 90%, about 99%, or about 99.9% of target microorganisms are unable to reproduce or survive.
The target temperature may also be a temperature below or above which the CSF is damaged or the proteins of the CSF are denatured. For example, albumin, which constitutes about 35% to about 80% of total protein in CSF, may be treated at 60° C. without being damaged. Ribonuclease (pH 2.0) may denature at about 30° C., ubiquitin (pH 4.0) may denature at about 82° C., and staphylococcal nuclease (pH 6.5) may denature at about 38° C. See Cristiano L. Dias, et al., The hydrophobic effect and its role in cold denaturation, 60 C
In some embodiments, the target temperature may be about 47° C. or about 45° C. In some embodiments, the target temperature may be about 37° C. to about 90° C., about 40° C. to about 80° C., about 45° C. to about 65° C., about 45° C. to about 60° C., about 45° C. to about 55° C., or about 50° C. In some embodiments, the target temperature may be a temperature above which a target microorganism reproduces and/or survives. For example, thermal death of C. neoformans begins at temperatures above 40° C. and increases rapidly as the temperature approaches 45° C. Accordingly, the temperature of the CSF may be increased within this range, or higher, to target C. neoformans. In some embodiments, the system may be configured to cool the CSF so the CSF reaches a target temperature by the time the CSF reaches a filter of the treatment unit 226. The target temperature may be a temperature below which a target microorganism reproduces and/or survives. In some embodiments, the target temperature may be below about 37° C., below about 30° C., below about 20° C., and/or below about 10° C. The system 100 may be configured to maintain the CSF at or near the target temperature for about 1 second to about 10 seconds or about 5 seconds. Other time ranges may be used as well. For example, about 1 second to about 10 minutes or about 5 seconds to about 5 minutes.
In some embodiments, the target may be a target protein that is the first or one of the first proteins to precipitate out of the CSF. This property of the target protein may enable it to be targeted for filtration or special processing. For example, the target protein may be precipitated out and then subject to special treatment (e.g., filtration, disposal, or other treatments). In some embodiments, the precipitated protein is added back to the solution.
In embodiments that warm the CSF, the system may be configured to allow the CSF to cool to about 37° C. or cooler before it is returned to the subject. In some embodiments, the CSF may cool quickly over short lengths of tubing. For example, in approximately six inches of tubing CSF flowing at a rate of at approximately one milliliter a minute may be cool from about 39° C. to about 22° C. In some embodiments, the tubing through which the treated CSF passes may be submerged in a cool bath to lower the temperature of the CSF. In other embodiments, the CSF may pass through a radiator or other cooling system. In embodiments that cool the CSF, the cooled CSF may be warmed or be allowed to warm before returning to the subject. It may also be beneficial to maintain the CSF in a cooled state as it is returned to the subject or otherwise cool the subject. Such benefits and techniques are described in U.S. patent application Ser. No. 15/287,174, entitled “Devices and Methods for Providing Focal Cooling to the Brain and Spinal Cord”, which was previously incorporated by reference. These benefits include inducing hypothermia, which can have neuroprotective effects.
Applying Light Treatment to the CSF
Some embodiments may utilize light to treat CSF. For example, ultraviolet (UV) light may be applied to the CSF in order to treat targets. As another example, photodynamic therapy may be used to treat targets.
The UV treatment system 500 may be configured to inactivate germs within the CSF. The dose of the UV treatment applied to the CSF may be a function of the intensity of the UV light and the time over which the UV light is applied to the CSF. For example, the dose may be described in terms of millijoules per square centimeter. A dose may be selected to inactivate about 99.9% of microorganisms. Such a dose may vary depending on the particular microorganism. See Gabriel Chevrefils, et al., UV Dose Required to Achieve Incremental Log Inactivation of Bacteria, Protozoa and Viruses, IUVA NEWS, vol. 8, no. 1, p. 38-45 (March 2006), incorporated by reference herein for any and all purposes as if set forth herein in its entirety. For example, a UV dose to inactivate Staphylococcus may be in the range of about 3 mJ/cm2 to about 8 mJ/cm2. Typical doses to inactivate bacteria may be in the range of about 2 mJ/cm2 to about 16 mJ/cm2. Typical doses to inactivate viruses may be about 4 mJ/cm2 to about 40 mJ/cm2. The wavelength of the UV light may be in the about 400 nm to about 100 nm range. A dose may be selected to inactivate a smaller percentage of microorganism, such as about 50%, about 75%, about 90%, about 95%, or other percentages. A dose may be selected to achieve a particular log reduction in the number of live germs, such as about a 1 log, 2 log, 3 log, 4 log, 5 log, 6 log, 7 log, or other log reduction. In some embodiments, reactor 502 may be configured such that CSF flowing through the reactor 502 may receive a particular dose of light. This may be accomplished by, for example, lengthening or shortening the fluid flow path and/or increase or decreasing the fluid flow speed of the CSF through the reactor 502.
In some embodiments, a method for treating the CSF with UV light may involve withdrawing a volume of CSF, applying a germicidal dose of UV light to the CSF, filtering the treated CSF, and returning the CSF to the subject. Withdrawing and returning the CSF may be performed according to various methods and systems described herein.
In some embodiments, photodynamic therapy may be used to treat targets. Photodynamic therapy may involve activating photosensitive substances with light. See Renato Prates, et al., Photodynamic therapy can kill Cryptococcus neoformans in in vitro and in vivo models, P
The systems and methods for applying photodynamic therapy may be similar to or the same as systems and methods for applying UV treatment. For example, photodynamic therapy may be applied using UV treatment system 500 using the UV lamp 508 or a different light source. A light source used for photodynamic therapy may be a lamp, laser or another source of electromagnetic radiation. The light source for photodynamic therapy may emit light at various wavelengths, including but not limited to a wavelength selected from the range of about 10 nanometers to about 1 millimeters. For example, the light source may be configured to emit light at a frequency of 660 nanometers.
Increasing CSF Flow Rate or Flow Volume
In typical TFF systems, high fluid flow rate and fluid flow volume is used to prevent membrane clogging and improve TFF performance and longevity. However, withdrawing fluid from and returning fluid to a subject at a high flow rate and high volumes presents challenges. In particular, should something go wrong with the system 100 (e.g., a clog or pinched tubing), high flow rates and high volumes may result in the system's problems quickly affecting the subject. For example, if CSF is withdrawn and returned to the patient at a high rate and there is a clog in the system 100 that prevents the return of CSF to the patient, a large amount of CSF may be withdrawn, causing problematically low levels of CSF within the subject.
In some embodiments, an array of micro-sized TFF systems may be used with a splitter. This system may be advantageous because the fluid flow rate may be faster through each of these TFF systems. Back pressure may be controlled across each of the micro-sized TFF systems.
In some embodiments, another liquid (e.g., artificial CSF, saline, or anther liquid) may be added to boost the amount of fluid moving through the treatment unit 226 to increase performance. The additional volume would enable additional fluid to pass through the treatment unit 226, thereby reducing the likelihood of the filter clogging.
In some embodiments, a volume of CSF may be removed from the patient, then no additional CSF is withdrawn or returned. The CSF isolated in the system 100 may then be filtered at a high speed without risk to the subject. Following sufficient processing, the filtered CSF may be returned and a next amount of CSF may be withdrawn.
Separating Cells Via their Dielectric Properties
Dielectrophoresis (DEP) is a technique in which a non-uniform electric field is applied to dielectric particles, thereby causing the particles to experience DEP forces. The way a particle responds to the non-uniform electric field depends on the particle's unique dielectric characteristics, including permittivity, conductivity, and capacitance. DEP may be used to electrically separate cells, particles, or other components of the CSF from each other or from the fluid itself. The non-uniform electric field that drives the particle movement and separation can be generated in various ways, ranging from spatial distortion of the field to different electrode configurations and geometries.
One application of DEP forces is to particles in a fluid flowing through a chamber. By manipulating the forces acting on the particles (e.g., a combination of hydrodynamic lift, sedimentation, and dielectrophoretic forces) through DEP, a system can alter and control the location of the particles in the fluid's velocity profile (speeding up or slowing down) and thus allow for separation from the rest of the fluid and removal of the particles. In addition, if multiple particles with different dielectric properties are present in a fluid, it is possible to separate them such that one type experiences positive DEP forces and the other type experiences negative DEP forces.
Because dielectric properties of particles (e.g., dielectric constant/permittivity, conductivity, and membrane capacitance) are dependent on size, structure, and composition, not only do cells have measurable dielectric properties, cells with different phenotypes have differing dielectric properties. Thus, DEP may be used to separate cells, particles, or other biomarkers of interest from each other or from fluid.
Advantageously, DEP separation uses no physical filter and does not have an associated risk of clogging. Additionally, DEP allows for targeted separation by targeting the unique inherent dielectric properties of cells, and can therefore separate different cell types from each other and selectively remove them.
In DEP, a non-uniform electric field is applied to a neutral or charged particle of interest to induce a force. The electric field may be induced using either alternating current or direct current. The magnitude and direction of force experienced by the particle depends on the particle and medium's electrical properties, size, shape, structure, composition of particle, frequency of applied E field, applied voltage, etc. Thus, the force can be manipulated for the desired application. Both positive and negative dielectrophoretic forces (FDEP) are possible. A positive FDEP means that the particle is attracted to the high-field regions (local E field maxima), and a negative DEP force means that the particle is attracted to the low-field regions (local E field minima). The determinant of whether the particle will experience a positive or a negative FDEP is the polarizability of the particle compared to the polarizability of the surrounding medium. If the polarizability of the particle is higher than that of the surrounding medium, it has more surface charges and will move toward the high field region (positive DEP force). If the opposite is true, the surrounding fluid will move toward the high field region and the particle will be pushed to the low field region (negative DEP force). FDEP is defined as
where εm and εp represent the medium and particle permittivities, respectively, and the term in brackets represents the Claussus Mossoti factor, which represents the relative permittivities of the particle with respect to the suspending medium. The permittivities are modelled as complex functions of the applied electric field, since the complex function allows for both a phase and magnitude (the causal behavior of the permittivity can be modeled as a phase difference), and the real part of this term is used in the FDEP calculation.
The non-uniform electric field can be generated by applying voltage across electrodes of appropriate geometry or by placement of insulators between electrodes to spatially distort the electric field. Geometry of electrodes other than parallel plates may generate non-uniform electric fields, although some geometries are more common than others for both design and efficiency purposes. The electrodes may be arranged in a microelectrode array. The length of the microelectrode array may be selected to optimize separation yields.
DEP may involve the manipulation of forces applied to particles in a fluid flowing through a column. A particle in a flowing fluid experiences a combination of hydrodynamic lift and sedimentation forces, and by applying an external dielectrophoretic force perpendicular to the flow of the fluid, a system can control the position of a particle of interest in a fluid's velocity profile, thus causing it to speed up or slow down since particles at different positions in the fluid's velocity profile travel at different velocities. The can facilitate separation and/or removal.
Differential dielectric affinity separation involves the separation of two different particle types by exploiting differences in the inherent dielectric properties of the two particles. An electric field may be applied such that one of the particle types experiences a positive FDEP while the other experiences a negative, thus separating the particles from each other.
Separation by differential dielectric affinity is affected by the frequency of the applied electric field. When the DEP response is plotted as a function of applied electric field frequency, the crossover frequency is defined as the x-intercept (the frequency at which the FDEP=0). When separating two different particles types, the system may be set to a frequency in between the crossover frequency of the two particles, such that one experiences a positive force and the other experiences a negative force.
The separation may cause a target type of particles to travel down a target path. In some embodiments, the target path may be through a porous membrane (e.g., membrane 258) on the sides of a fluid pathway. In particular, the target molecule may be attracted to an electrode on the other side of the membrane. The target particle may be pass through the filter. Once the target particle passes through the membrane, it may be prevented or discouraged from returning to the other side of the membrane.
In some embodiments, the target path may be a particular path at an intersection. For example, there may be a Y-junction in a flow path. The target particles may be pulled in a particular direction, so they are more likely to flow in one direction over another. This filtration may be a statistical process and be performed several times so there is a particular level of filtration (e.g., 99.9% filtration). In this process, there may be separate side loops that work through the separated material at a high rate. In some embodiments, there may be more than two potential flow paths. For example, there may be three different flow paths at a particular junction. The different flow paths may be separated based on the target molecule. In some embodiments, the particular flow paths may be subjected to different levels of treatment.
Many diseases of the central nervous system manifest in the CSF and show CSF dissemination of certain foreign/unwanted matter such as cells, proteins, or other molecules. It would be advantageous to have a method to specifically target and separate these particles from each other or from the fluid itself based on their inherent dielectric characteristics. Some embodiments may be directed to a method of electrical separation that allows for the application of CSF therapeutics to a wider range of central nervous system disease states (other than subarachnoid hemorrhage-induced cerebral vasospasm) that allows for specific targeting and removal without the use of a physical filter.
Examples of targets include leptomeningeal carcinomatosis tumor cells, which may be present in the CSF and resulting from metastases of various cancers. Similarly, glioblastoma, a rapidly-progressing and usually fatal tumor that generally forms in the central hemispheres of the brain and arises from astrocytes, tumor cells may disseminate in the CSF. CSF dissemination occurs in 10-27% of cases of glioblastoma patients. See, e.g., Cerebral Glioblastoma with Cerebrospinal Fluid Dissemination, N
Many DEP research studies perform separation experiments in a series of discontinuous steps involving a loading of the suspension step, a washing step, and an elution step. Such discontinuous procedures limit the separation throughput and scaling of the technique and would make integration of the DEP separator with a CSF treatment system difficult. Thus it may be desirable to implement a continuous system. See Ki-Ho Han, et al., Lateral-Driven Continuous Dielectrophoretic Microseparators for Blood Cells Suspended in a Highly Conductive Medium, L
The medium in which the target is located is also a factor in applying DEP to CSF. The relative polarizability (which depends on permittivity and conductivity) of the particle with respect to the medium determines whether a particle will experience a positive or negative FDEP. A particle that is more polarizable than the surrounding medium will experience a positive DEP force, and vice versa. Most DEP separation studies control the conductivity of the suspension medium to ensure a low conductivity (compared to physiological medium) of about 30-60 mS/m, to optimize parameters for strong positive DEP separation forces. However, controlling the conductivity of the medium is not clinically relevant and a low conductivity suspension medium is not physiologically relevant since physiological fluids usually have higher conductivities (10-100 times higher than mediums used in many DEP experiments). The electrical conductivity of the CSF at body temperature may be approximately 1790 mS/m, which is about two orders of magnitude higher than the conductivity of mediums used in many DEP research studies. Stephen B. Baumann, et al., The Electrical Conductivity of Human Cerebrospinal Fluid at Body Temperature, IEEE T
Most cells in CSF would experience negative DEP forces at a wide range of E field frequencies, because CSF is a highly conductive suspension medium. Ki-Ho Han, et al., Lateral-Driven Continuous Dielectrophoretic Microseparators for Blood Cells Suspended in a Highly Conductive Medium, L
DEP separators may be scaled to handle larger volumes of fluid; however, many DEP separators used in research studies are limited to microfluidics applications with low throughput. The main reason for this is that electric field intensity decays exponentially with increasing distance from electrodes, and FDEP is proportional to the electric field intensity. Studies using planar microelectrode arrays, which usually lie at the bottom of the chamber, are limited in column height and thus volume of fluid they can process because the E field is inversely proportional to the square of the distance from electrodes; a particle in the fluid towards top of chamber (farther away from the electrodes) may not be exposed to the E field, or may not be exposed to enough E field for it to experience an appreciable force necessary for separation.
A potential solution to this is the use of 3D microelectrode array (MEA) designs. As opposed to a planar microelectrode array resting on the bottom of the column, 3D MEAs would extend the E field further up into fluid, allowing particles in all locations of the fluid's velocity profile to experience an appreciable dielectrophoretic force. 3D microelectrodes may affect the fluid's velocity profile. The fluid's velocity profile can be modeled using Navier-Stokes equations and finite-element analysis.
Studies have proposed the use of carbon microfabrication techniques to correlate the electric field distribution with the velocity profile of the fluid. Benjamin Y. Park, et al., 3-D Electrode Designs for Flow-through Dielectrophoretic Systems, E
Options for 3D electrode design include extensions of 2D designs, or other designs.
A potential advantage of electrical separation is that since there is no use of a physical filter, there is reduced risk of clogging and the filtration is not limited by the size of the particles of interest. For example, consider a situation in which it was desirable to separate two particles of the same size/mass from each other, or if multiple particles of the same size/mass were present in the fluid and it was desirable to only remove one type of particle from the fluid. In either of these cases, electrical separation could be an option for purification since size/mass-based filtration would not be applicable.
Because DEP exploits inherent dielectric characteristic differences between cells of differing phenotypes, it has the potential to be broadly applicable to a range of central nervous system disease states.
There may be challenges associated with this technique. For example, electrode surfaces may become saturated with cells after a period of time (e.g., approximately 30 minutes). In general, if the concentration of the target particle in the fluid is too high, the electrode surfaces and/or areas where particles are being collected may become saturated after a certain period of time. This would result in a decrease in separation efficiency and cells would cease being separated from the fluid (e.g., CSF would mostly likely just continue being circulated as opposed to circulated and purified). Thus, the concentration of the target molecule in the CSF may be a consideration.
In some embodiments, a method for treating the CSF with dielectric separation may involve withdrawing a volume of CSF and encouraging target molecules to flow in a particular direction or along a specific path by inducing an electric field through the CSF. Withdrawing the CSF may be performed according to various methods and systems described herein.
In some embodiments, a method for treating the CSF with dielectric separation may involve withdrawing a volume of CSF, capturing target molecules (e.g., at electrode surfaces or in collection wells) by applying an electric field to the CSF, and returning the processed CSF to the subject.
Applying Spiral and/or Centrifugal Separation
In some embodiments, a method for applying spiral and/or centrifugal separation may include withdrawing a volume of CSF, passing the volume of CSF through a hydrocyclone to separate the CSF into first and second volumes, and returning one of the first or second volumes to the subject. Withdrawing and returning the CSF may be performed according to various methods and systems described herein.
Binding Additives to Target Molecules
Some systems and methods may involve introducing an additive into the CSF. This step may include directly introducing the additive into the treatment site 112 (e.g., via port 124) or by other means (e.g., such as an orally-administered substance). In some embodiments, the additive is added to the CSF after the CSF has been removed from the treatment site 112. The additive may serve various purposes, including but not limited to improving the effectiveness of the treatment system 102 (e.g., by making a material more easily filtered-out by a filter of the treatment system 102), increasing the safety of the procedure, improving the health of the patient, or other purposes. For example, in certain embodiments, the additive may be a binding drug, molecule, salt, or other binding material. The binding additive may preferentially bind to certain target materials within the CSF to modify how the material interacts with the treatment system 102.
For example, in certain embodiments, the binding additive may preferentially bind to a target material (e.g., a protein or cytokine), causing the target to become larger in size or precipitate out, thereby making the target more easily removed by a filter of the treatment system 102. In certain embodiments, the additive may be configured to change a dielectric property of the target to make the target more or less easily filtered by a filter of the treatment system 102. In certain embodiments, the additive is given a particular amount of time to work or otherwise interact with target before a next step is taken. For example, there may be a waiting period after the additive has been introduced to the CSF to give the additive time to bind with or otherwise modify the target before the CSF is filtered or otherwise processed.
In some embodiments, an additive has specific properties (e.g., size, mass, dielectric constant, magnetism, etc.), which may be used to target particular targets (e.g., by chemically or biologically targeting a protein or some other tag). The additive molecules may attach to the target particle, so the target particle is more easily separable from the CSF. For example, the additive molecule may make the particle of interest larger so the additive-target combination may be more easily separated by size-exclusion filtration. The additive-target combination may be heavier to encourage separation by centrifugal filtration (e.g., as described above). The additive-target combination may have altered dielectric properties, making it more easily separable using the dielectric separation method.
As a particular example, a health care professional may desire to a remove a target protein, and introduce a gold micro or nano particle additive to the CSF. The additive may have a tag (e.g., a chemical tag) for the target. The additive may then attach to the target, making the additive-target combination larger or otherwise more easily filtered. The now-larger additive-target combination is then more easily removed.
In some embodiments, a treatment system 102 may include a pre-mixing system in which the additive is mixed with the CSF. The pre-mixing system may be configured to cause the additive to mix with the CSF and react with the target. The pre-mixing system may be configured with particular parameters, such as a particular temperature, pressure, or other conditions. The pre-mixing system may be configured such that the additive is allowed to react with the target for a particular amount of time before the CSF leaves the system. The additive-target combination may then move through the system and eventually be filtered out (e.g., using a dead end filter).
In some embodiments, the separated additive-target combination is deposited into a waste bag. The additive-target combination may be separated from the CSF in the waste bag (e.g., because the additive-target combination sank to the bottom of the waste bag) and the CSF in the waste bag may be recycled into the system 100. For example, the CSF may be added back to an inflow of the treatment system 102 and processed again.
In some embodiments, the additive includes magnetic nanobeads configured to capture particular molecules, pathogens, germs, toxins, or other targets. For example, the magnetic nanobeads may be coated with engineered human opsonin (mannose-binding lectin), which may capture a wide variety of targets. Once the additive binds to the target, the additive-target combination may be separated from the CSF using a magnet.
Combined Systems
In some embodiments, there may be multiple divided subloops (in parallel or series) that have different treatments and are recombined as necessary. The different loops may enable different treatment. For example, one loop may be con figured to use UV light to kill bacteria and then the fluid passes through a different subloop configured to heat the fluid to slow reproduction of fungus and then cooling the CSF before it is returned to the subject. In some embodiments, vibrating the treatment unit 226 may discourage clogging, coagulating, clotting, and settling on the treatment unit 226.
Multiple systems may be used to provide incremental enhancements to the CSF prior to filtration. For example, filtering using a hydrocyclone and dielectric separation techniques may remove a percentage of the target molecules, with the remaining amount removed by a TFF system. While not necessarily removing the need for a filtering system, the hydrocyclone and dielectric separation may remove an amount of target (or other) particles to improve performance of a treatment system.
Targets
The targets may be any kind of biomarker, the removal of which is or may be associated with particular health outcomes for the subject. In some embodiments, the target may be an organism known to or thought to cause a particular disease or health condition, such as meningitis. In some embodiments, the targets may be metastases. In some embodiments, the target may be polysaccharide capsules. For example, some germs, such as Cryptococcus and Neisseria meningitides, are encapsulated in a polysaccharide capsule. After the germ sheds the capsule, the capsule may be suspended within the CSF. Both the germ and the capsule may be targeted for removal. While the germ may be a primary target, the capsule is relatively large and may problematically cause clogging in some filters. As another example, glial fibrillary acid proteins may be targeted. These proteins may be a marker for astrocytic differentiation in patients with cerebral glioblastoma. Other markers of CSF dissemination of glioblastoma may also be removed.
There are a number of cytokines that have been implicated in inflammation in acute brain injury and chronic brain injury, which may also be a target. Similar to other disease processes, the early stage of inflammation can facilitate healing but inflammation that increases over time and becomes “chronic” can have severe long-term effects on cognition and overall mental health.
Embodiments may enable filtration of cytokines like TNF-α, interleukins and other cytokines from the CSF of a compromised brain. By actively decreasing the cytokine load, during a chronic inflammation, overall brain health would improve significantly. Removal of substances in the 25 kDa to 80 kDA range would be important to protect on the filtration side.
Examples of cytokines and other proteins that may be targeted may include, but need to be limited to, EGF, Eotaxin, E-selectin, fas ligand, FGF2, Flt3 lig, fractalkine, G-CSF, GM-CSF, GRO, ICAM, IFNa2, IFNg, IL10, IL12p40, IL12p70, IL13, IL15, IL17, IL1a, IL1b, IL1ra, IL2, IL3, IL4, IL5, IL6, IL7, IL8, IL9, integrins, IP10, L-selectin, MCP1, MCP3, MDC, MIP1a, MIP1b, PDGF-AA, PDGF-AAAB, P-selectin, RANTES, sCD40L, sIL2R, TGFa, TNF, TNFb, VCAM, VEGF, and others. In some embodiments, the treatment unit 226 may be configured to capture and absorb cytokines in the about 10 to about 50 kDa range where most cytokines reside.
Various journal articles and other publications are cited in this disclosure. Each of those is hereby incorporated by reference herein for any and all purposes, as if fully set forth herein.
Within this disclosure, connection references (for example, attached, coupled, connected, and joined) may include intermediate members between a collection of components and relative movement between components. Such references do not necessarily infer that two components are directly connected and in fixed relation to each other. The exemplary drawings are for purposes of illustration only and the dimensions, positions, order and relative sizes reflected in the drawings attached hereto may vary.
The above specification provides a complete description of the structure and use of exemplary embodiments as claimed below. Although various embodiments of the invention as claimed have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this disclosure. Other embodiments are therefore contemplated. It is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative only of particular embodiments and not limiting. Changes in detail or structure may be made without departing from the basic elements of the disclosure as defined in the following claims.
This application is a continuation of U.S. patent application Ser. No. 15/367,592, filed Dec. 2, 2016, which issued as U.S. Pat. No. 10,532,195, which claims the benefit of priority under 35 U.S.C. § 119 of the earlier filing date of U.S. Provisional Patent Application No. 62/263,305, filed Dec. 4, 2015, entitled “Systems and Methods for the Conditioning of Cerebrospinal fluid,” each of which is hereby fully incorporated by reference for any and all purposes as if fully set forth herein in their entireties. Embodiments described in this application may be used in combination or conjunction with the subject matter described in one or more of the following, each of which is hereby fully incorporated by reference for any and all purposes as if set forth herein in their entireties: U.S. Pat. No. 8,435,204, entitled “Cerebrospinal Fluid Purification System,” which issued May 7, 2013, which is the U.S. National Phase entry of International Patent Application Number PCT/US2007/080834, filed Oct. 9, 2007, which claims the benefit of priority of U.S. Provisional Application No. 60/828,745, filed on Oct. 9, 2006; U.S. patent application Ser. No. 14/743,652, filed Jun. 18, 2015, entitled “Devices and Systems for Access and Navigation of Cerebrospinal Fluid Space,” which claims the benefit of priority of U.S. Provisional Application No. 62/038,998, filed on Aug. 19, 2014; U.S. patent application Ser. No. 13/801,215, filed Mar. 13, 2013, entitled “Cerebrospinal Fluid Purification System,” which is a continuation of U.S. patent application Ser. No. 12/444,581, filed Jul. 1, 2010, which issued as U.S. Pat. No. 8,435,204 and is the U.S. National Phase entry of International Patent Application Number PCT/US2007/080834, filed Oct. 9, 2007, which claims the benefit of priority of U.S. Provisional Application No. 60/828,745, filed on Oct. 9, 2006; and U.S. patent application Ser. No. 15/287,174, filed Oct. 6, 2016, entitled “Devices and Methods for Providing Focal Cooling to the Brain and Spinal Cord,” which claims the benefit of priority of U.S. Provisional Patent Application No. 62/237,867, filed Oct. 6, 2015.”
| Number | Name | Date | Kind |
|---|---|---|---|
| 2969066 | Holter et al. | Jan 1961 | A |
| 3419010 | Williamson | Dec 1968 | A |
| 3867937 | Schwartz | Feb 1975 | A |
| 3889687 | Harris et al. | Jun 1975 | A |
| 4378797 | Osterholm | Apr 1983 | A |
| 4446154 | Osterholm | May 1984 | A |
| 4451251 | Osterholm | May 1984 | A |
| 4551137 | Osborne | Nov 1985 | A |
| 4686085 | Osterholm | Aug 1987 | A |
| 4695541 | Taylor | Sep 1987 | A |
| 4767409 | Brooks | Aug 1988 | A |
| 4830849 | Osterholm | May 1989 | A |
| 4888115 | Marinaccio et al. | Dec 1989 | A |
| 4904237 | Janese | Feb 1990 | A |
| 4950232 | Ruzicka et al. | Aug 1990 | A |
| 4958901 | Coombs | Sep 1990 | A |
| 5160323 | Andrew | Nov 1992 | A |
| 5171226 | McCrory | Dec 1992 | A |
| 5190529 | McCrory et al. | Mar 1993 | A |
| 5334315 | Matkovich et al. | Aug 1994 | A |
| 5396899 | Strittmatter | Mar 1995 | A |
| 5405316 | Magram | Apr 1995 | A |
| 5423738 | Robinson et al. | Jun 1995 | A |
| 5456843 | Koenhen | Oct 1995 | A |
| 5462667 | Wollinsky et al. | Oct 1995 | A |
| 5531673 | Helenowski | Jul 1996 | A |
| 5560828 | Wenten | Oct 1996 | A |
| 5601727 | Bormann et al. | Feb 1997 | A |
| 5683357 | Magram | Nov 1997 | A |
| 5726026 | Wilding et al. | Mar 1998 | A |
| 5755968 | Stone | May 1998 | A |
| 5772607 | Magram | Jun 1998 | A |
| 5836928 | Gerber et al. | Nov 1998 | A |
| 5897528 | Schultz | Apr 1999 | A |
| 5941853 | Collins | Aug 1999 | A |
| 5947689 | Schick | Sep 1999 | A |
| 5948441 | Lenk et al. | Sep 1999 | A |
| 5980480 | Rubenstein et al. | Nov 1999 | A |
| 6013051 | Nelson | Jan 2000 | A |
| 6022742 | Kopf | Feb 2000 | A |
| 6056725 | Elsberry | May 2000 | A |
| 6113797 | Al-Samadi | Sep 2000 | A |
| 6217552 | Barbut et al. | Apr 2001 | B1 |
| 6238382 | Schock et al. | May 2001 | B1 |
| 6264625 | Rubenstein et al. | Jul 2001 | B1 |
| 6269699 | Gilman et al. | Aug 2001 | B1 |
| 6326044 | Lindquist | Dec 2001 | B1 |
| 6379331 | Barbut et al. | Apr 2002 | B2 |
| 6383159 | Saul et al. | May 2002 | B1 |
| 6383380 | Kopf | May 2002 | B1 |
| 6387290 | Brody et al. | May 2002 | B1 |
| 6468219 | Njemanze | Oct 2002 | B1 |
| 6537241 | Odland | Mar 2003 | B1 |
| 6558353 | Zohmann | May 2003 | B2 |
| 6575928 | Saul et al. | Jun 2003 | B2 |
| 6594880 | Elsberry | Jul 2003 | B2 |
| 6641563 | Vitullo et al. | Nov 2003 | B1 |
| 6682508 | Meythaler et al. | Jan 2004 | B1 |
| 6689085 | Rubenstein et al. | Feb 2004 | B1 |
| 6689756 | Hesson et al. | Feb 2004 | B2 |
| 6709426 | Gijsbers et al. | Mar 2004 | B2 |
| 6733675 | Ando et al. | May 2004 | B2 |
| 6758832 | Barbut et al. | Jul 2004 | B2 |
| 6830561 | Jansen et al. | Dec 2004 | B2 |
| 6849185 | Wu et al. | Feb 2005 | B1 |
| 6875192 | Saul et al. | Apr 2005 | B1 |
| 6969383 | Hildebrand | Nov 2005 | B2 |
| 7011647 | Purdy et al. | Mar 2006 | B2 |
| 7025742 | Rubenstein et al. | Apr 2006 | B2 |
| 7108680 | Rohr et al. | Sep 2006 | B2 |
| 7118549 | Chan | Oct 2006 | B2 |
| 7150737 | Purdy et al. | Dec 2006 | B2 |
| 7181289 | Pflueger et al. | Feb 2007 | B2 |
| 7189221 | Silverberg et al. | Mar 2007 | B2 |
| 7214211 | Woehr et al. | May 2007 | B2 |
| 7252659 | Shehada et al. | Aug 2007 | B2 |
| 7318834 | Njemanze | Jan 2008 | B2 |
| 7455666 | Purdy | Nov 2008 | B2 |
| 7708716 | Shah | May 2010 | B2 |
| 7787954 | Purdy | Aug 2010 | B2 |
| 7842002 | Mantle | Nov 2010 | B2 |
| 7850723 | Magers | Dec 2010 | B1 |
| 7887503 | Geiger | Feb 2011 | B2 |
| 8029495 | Pyles | Oct 2011 | B2 |
| 8131353 | Purdy | Mar 2012 | B2 |
| 8137334 | Heruth et al. | Mar 2012 | B2 |
| 8231586 | Kizer et al. | Jul 2012 | B2 |
| 8357296 | Bonhomme et al. | Jan 2013 | B2 |
| 8398581 | Panotopoulos | Mar 2013 | B2 |
| 8435204 | Lad et al. | May 2013 | B2 |
| 8444661 | Nair et al. | May 2013 | B2 |
| 8475419 | Eckermann | Jul 2013 | B2 |
| 8486023 | Pyles | Jul 2013 | B2 |
| 8486104 | Samson et al. | Jul 2013 | B2 |
| 8512280 | Rozenberg et al. | Aug 2013 | B2 |
| 8518636 | Bosch et al. | Aug 2013 | B2 |
| 8523930 | Saunders et al. | Sep 2013 | B2 |
| 8603057 | Hoffman et al. | Dec 2013 | B2 |
| 8669044 | Chiu et al. | Mar 2014 | B2 |
| 8679751 | Huang | Mar 2014 | B2 |
| 8721642 | Sullivan | May 2014 | B1 |
| 8905968 | Thomas | Dec 2014 | B2 |
| 9205184 | Eckermann | Dec 2015 | B2 |
| 9211163 | Jaramaz et al. | Dec 2015 | B1 |
| 9387311 | Heilman et al. | Jul 2016 | B1 |
| 9770180 | Radojicic | Sep 2017 | B2 |
| 9895518 | Lad et al. | Feb 2018 | B2 |
| 10272188 | Geiger et al. | Apr 2019 | B1 |
| 10695545 | Hedstrom | Jun 2020 | B2 |
| 20020077682 | Lee et al. | Jun 2002 | A1 |
| 20020123714 | Saul et al. | Sep 2002 | A1 |
| 20020156482 | Scribner et al. | Oct 2002 | A1 |
| 20020193285 | Hesson et al. | Dec 2002 | A1 |
| 20020198579 | Khanna | Dec 2002 | A1 |
| 20030004495 | Saul | Jan 2003 | A1 |
| 20030014016 | Purdy | Jan 2003 | A1 |
| 20030028137 | Levin | Feb 2003 | A1 |
| 20030032915 | Saul | Feb 2003 | A1 |
| 20030063509 | Yamasaki | Apr 2003 | A1 |
| 20030072761 | LeBowitz | Apr 2003 | A1 |
| 20030083698 | Whitehurst et al. | May 2003 | A1 |
| 20030097082 | Purdy et al. | May 2003 | A1 |
| 20030129134 | Chenard et al. | Jul 2003 | A1 |
| 20030130577 | Purdy et al. | Jul 2003 | A1 |
| 20030130651 | Lennox | Jul 2003 | A1 |
| 20030135196 | Hesson et al. | Jul 2003 | A1 |
| 20030163181 | Frazer et al. | Aug 2003 | A1 |
| 20030199802 | Barbut | Oct 2003 | A1 |
| 20040015133 | Karim | Jan 2004 | A1 |
| 20040030279 | Rubenstein et al. | Feb 2004 | A1 |
| 20040068221 | Silverberg et al. | Apr 2004 | A1 |
| 20040138125 | Wang | Jul 2004 | A1 |
| 20040138728 | Wong et al. | Jul 2004 | A1 |
| 20040142906 | Wang | Jul 2004 | A1 |
| 20040147987 | Ginsburg et al. | Jul 2004 | A1 |
| 20040210231 | Boucher et al. | Oct 2004 | A1 |
| 20040215162 | Putz | Oct 2004 | A1 |
| 20040220545 | Heruth et al. | Nov 2004 | A1 |
| 20050004504 | Frye et al. | Jan 2005 | A1 |
| 20050060006 | Pflueger et al. | Mar 2005 | A1 |
| 20050090801 | Racz et al. | Apr 2005 | A1 |
| 20060015160 | Lamard | Jan 2006 | A1 |
| 20060016751 | Ali et al. | Jan 2006 | A1 |
| 20060030027 | Ellson et al. | Feb 2006 | A1 |
| 20060045796 | Anderle et al. | Mar 2006 | A1 |
| 20060058836 | Bose et al. | Mar 2006 | A1 |
| 20060142783 | Lewis et al. | Jun 2006 | A1 |
| 20060175543 | Elefteriades | Aug 2006 | A1 |
| 20060184098 | Barnitz et al. | Aug 2006 | A1 |
| 20060224101 | Glenn | Oct 2006 | A1 |
| 20060254984 | Polyakov | Nov 2006 | A1 |
| 20060282043 | Pyles | Dec 2006 | A1 |
| 20070050002 | Elefteriades | Mar 2007 | A1 |
| 20070246406 | Dibel et al. | Oct 2007 | A1 |
| 20080045883 | Radojicic | Feb 2008 | A1 |
| 20080154181 | Khanna | Jun 2008 | A1 |
| 20080171990 | Zauner | Jul 2008 | A1 |
| 20080190848 | Oklejas | Aug 2008 | A1 |
| 20080249458 | Yamasaki | Oct 2008 | A1 |
| 20080249501 | Yamasaki | Oct 2008 | A1 |
| 20080319376 | Wilcox et al. | Dec 2008 | A1 |
| 20090076357 | Purdy | Mar 2009 | A1 |
| 20090082800 | Janardhan | Mar 2009 | A1 |
| 20090105737 | Fulkerson et al. | Apr 2009 | A1 |
| 20090171369 | Gayzik | Jul 2009 | A1 |
| 20090277850 | Adams et al. | Nov 2009 | A1 |
| 20100030196 | Hildebrand et al. | Feb 2010 | A1 |
| 20100145267 | Bishop et al. | Jun 2010 | A1 |
| 20100168665 | Skerven | Jul 2010 | A1 |
| 20100179509 | Pyles | Jul 2010 | A1 |
| 20100198195 | Nishtala et al. | Aug 2010 | A1 |
| 20100204672 | Lockhart et al. | Aug 2010 | A1 |
| 20100260815 | Kyle et al. | Oct 2010 | A1 |
| 20100280438 | Thomas | Nov 2010 | A1 |
| 20100305492 | Lad et al. | Dec 2010 | A1 |
| 20100324397 | Purdy | Dec 2010 | A1 |
| 20110029050 | Elefteriades et al. | Feb 2011 | A1 |
| 20110046547 | Mantle | Feb 2011 | A1 |
| 20110098623 | Zhang et al. | Apr 2011 | A1 |
| 20110190831 | Mafi et al. | Aug 2011 | A1 |
| 20110319824 | Pyles | Dec 2011 | A1 |
| 20120004625 | Velez-Rivera | Jan 2012 | A1 |
| 20120149021 | Yung et al. | Jun 2012 | A1 |
| 20120165757 | Purdy | Jun 2012 | A1 |
| 20120203142 | Bedell | Aug 2012 | A1 |
| 20120203290 | Warren et al. | Aug 2012 | A1 |
| 20120209367 | Prindle et al. | Aug 2012 | A1 |
| 20120232458 | Herschman | Sep 2012 | A1 |
| 20120234694 | Vecitis et al. | Sep 2012 | A1 |
| 20120253266 | Qureshi et al. | Oct 2012 | A1 |
| 20120302938 | Browd et al. | Nov 2012 | A1 |
| 20120330196 | Nita | Dec 2012 | A1 |
| 20130023814 | Bertrand et al. | Jan 2013 | A1 |
| 20130030411 | Kreck et al. | Jan 2013 | A1 |
| 20130035628 | Garrison et al. | Feb 2013 | A1 |
| 20130066331 | Chitre et al. | Mar 2013 | A1 |
| 20130085413 | Tsamir et al. | Apr 2013 | A1 |
| 20130131811 | Barreiro et al. | May 2013 | A1 |
| 20130158470 | Panotopoulos | Jun 2013 | A1 |
| 20130158564 | Harris et al. | Jun 2013 | A1 |
| 20130165903 | Webler et al. | Jun 2013 | A1 |
| 20130197422 | Browd et al. | Aug 2013 | A1 |
| 20130248450 | Kenley et al. | Sep 2013 | A1 |
| 20140066830 | Lad et al. | Mar 2014 | A1 |
| 20140166555 | Dibel et al. | Jun 2014 | A1 |
| 20140194840 | Eckermann | Jul 2014 | A1 |
| 20140276334 | Eckermann | Sep 2014 | A1 |
| 20140276660 | Eckermann | Sep 2014 | A1 |
| 20140299546 | Eckert et al. | Oct 2014 | A1 |
| 20140316373 | Dhall | Oct 2014 | A1 |
| 20140323857 | Mourad et al. | Oct 2014 | A1 |
| 20140358183 | Saunders et al. | Dec 2014 | A1 |
| 20150094644 | Lenihan et al. | Apr 2015 | A1 |
| 20150196742 | Browd et al. | Jul 2015 | A1 |
| 20150223832 | Swaney et al. | Aug 2015 | A1 |
| 20150224284 | Panotopoulos et al. | Aug 2015 | A1 |
| 20150238682 | Feranuma et al. | Aug 2015 | A1 |
| 20150238685 | Elias et al. | Aug 2015 | A1 |
| 20150257774 | Galdonik et al. | Sep 2015 | A1 |
| 20150328295 | Lodge et al. | Nov 2015 | A1 |
| 20160051801 | Vase | Feb 2016 | A1 |
| 20160101270 | Browd et al. | Apr 2016 | A1 |
| 20160136398 | Heilman et al. | May 2016 | A1 |
| 20160174995 | Turjman et al. | Jun 2016 | A1 |
| 20160303355 | Heilman et al. | Oct 2016 | A1 |
| 20160303356 | Heilman et al. | Oct 2016 | A1 |
| 20170000361 | Meyering et al. | Jan 2017 | A1 |
| 20170035950 | Meyering et al. | Feb 2017 | A1 |
| 20170035998 | Meyering et al. | Feb 2017 | A1 |
| 20170095649 | Vase et al. | Apr 2017 | A1 |
| 20170157374 | Hedstrom et al. | Jun 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 2407214 | Apr 2003 | CA |
| 2597293 | Aug 2006 | CA |
| 2793672 | Sep 2011 | CA |
| 2936349 | Jul 2015 | CA |
| 101288783 | Oct 2008 | CN |
| 101653637 | Feb 2010 | CN |
| 202409608 | Sep 2012 | CN |
| 102973305 | Mar 2013 | CN |
| 203816046 | Sep 2014 | CN |
| 203935243 | Nov 2014 | CN |
| 105361923 | Mar 2016 | CN |
| 515007 | Dec 1996 | EP |
| 1331019 | Jul 2003 | EP |
| 2217315 | May 2012 | EP |
| 2583744 | Apr 2013 | EP |
| 2695633 | Feb 2014 | EP |
| 2882483 | Dec 2014 | EP |
| 2365344 | Feb 2002 | GB |
| H03504681 | Oct 1989 | JP |
| 2001509712 | Jul 2001 | JP |
| 2001513349 | Sep 2001 | JP |
| 2002514096 | May 2002 | JP |
| 2003515394 | May 2003 | JP |
| 2003250881 | Sep 2003 | JP |
| 2003526398 | Sep 2003 | JP |
| 2004508109 | Mar 2004 | JP |
| 2004236792 | Aug 2004 | JP |
| 2004528062 | Sep 2004 | JP |
| 2006514857 | May 2006 | JP |
| 2006525827 | Nov 2006 | JP |
| 2010505556 | Feb 2010 | JP |
| 2010520446 | Jun 2010 | JP |
| 2011526799 | Oct 2011 | JP |
| 2012066103 | Apr 2012 | JP |
| 2100965 | Jan 1998 | RU |
| 2158613 | Nov 2000 | RU |
| 2290974 | Jan 2007 | RU |
| 2312678 | Dec 2007 | RU |
| 2314838 | Jan 2008 | RU |
| 8909629 | Oct 1989 | WO |
| 9205864 | Apr 1992 | WO |
| 9802202 | Jan 1998 | WO |
| 9833535 | Aug 1998 | WO |
| 9907276 | Feb 1999 | WO |
| 0041762 | Jul 2000 | WO |
| 0043056 | Jul 2000 | WO |
| 0051669 | Sep 2000 | WO |
| 0139819 | Jun 2001 | WO |
| 0154766 | Aug 2001 | WO |
| 0211703 | Feb 2002 | WO |
| 0220083 | Mar 2002 | WO |
| 0232494 | Apr 2002 | WO |
| 02056937 | Jul 2002 | WO |
| 03015710 | Feb 2003 | WO |
| 03020208 | Mar 2003 | WO |
| 03057306 | Jul 2003 | WO |
| 2004041314 | May 2004 | WO |
| 2004060463 | Jul 2004 | WO |
| 2004072647 | Aug 2004 | WO |
| 2004093945 | Nov 2004 | WO |
| 2004105839 | Dec 2004 | WO |
| 2005035025 | Apr 2005 | WO |
| 2005044335 | May 2005 | WO |
| 2005044847 | May 2005 | WO |
| 2006017763 | Feb 2006 | WO |
| 2006079007 | Jul 2006 | WO |
| 2006086195 | Aug 2006 | WO |
| 2007013945 | Feb 2007 | WO |
| 2007110643 | Oct 2007 | WO |
| 2008105959 | Sep 2008 | WO |
| 2008107652 | Sep 2008 | WO |
| 2009114046 | Sep 2009 | WO |
| 2009140202 | Nov 2009 | WO |
| 2009155384 | Dec 2009 | WO |
| 2009155614 | Dec 2009 | WO |
| 2010014447 | Feb 2010 | WO |
| 2010123558 | Oct 2010 | WO |
| 2010127071 | Nov 2010 | WO |
| 2011060317 | May 2011 | WO |
| 2011114260 | Sep 2011 | WO |
| 2011150323 | Dec 2011 | WO |
| 2012099984 | Jul 2012 | WO |
| 2013034602 | Mar 2013 | WO |
| 2013052951 | Apr 2013 | WO |
| 2014023551 | Feb 2014 | WO |
| 2014023552 | Feb 2014 | WO |
| 2014039780 | Mar 2014 | WO |
| 2014160481 | Aug 2014 | WO |
| 2015104631 | Jul 2015 | WO |
| 2015109260 | Jul 2015 | WO |
| 2015157320 | Oct 2015 | WO |
| 2016007553 | Jan 2016 | WO |
| Entry |
|---|
| Extended EP Search Report dated Mar. 4, 2019 for EP application No. 16833454.8, 7 pages. |
| Madeira-Lopes, et al., “Comparative study of the temperature profiles of growth and death of the pathogenic yeast Cryptococcus neoformans and the non-pathogenic Cryptococcus albidus”, J Basic Microbiol., 26:43-47, 1986. |
| Dias, et al., “The hydrophobic effect and its role in cold denaturation”, Cryobiology, 60: 91-99, 2010. |
| Chevrefils, et al., “UV Dose Required to Achieve Incremental Log Inactivation of Bacteria, Protozoa and Viruses”, IUVA News, 8(1): 38-45, Mar. 2006. |
| Prates, et al., “Photodynamic therapy can kill Cryptococcus neoformans in in vitro and in vivo models”, Proc. of Spie, vol. 7165, 2009. |
| Pitera, et al., “Dielectric Properties of Proteins from Simulation: The Effects of Solvent, Ligands, pH, and Temperature”, Biophysical Journal, 80(6): 2546-2555, Jun. 2001. |
| Han, et al., “Lateral-Driven Continuous Dielectrophoretic Microseparators for Blood Cells Suspended in a Highly Conductive Medium”, Lab on a Chip, 8(7):1079-1086, Jun. 27, 2008. |
| Baumann, et al., “The Electrical Conductivity of Human Cerebrospinal Fluid at Body Temperature”, IEEE Transactions on Biomedical Engineering, 44(3): 220-223, Mar. 1997. |
| Huang, et al., “Electrode Design for Negative Dielectrophoresis”, Measurement Science and Technology, 2(12): 1142-1146, Dec. 1, 1991. |
| Chen, et al., “A 3D Paired Microelectrode Array for Accumulation and Separation of Microparticles”, J. of Micromechanics and Microengineering, 16(7): 1162-1169, Apr. 28, 2006. |
| Stephens et al; “The Dielectrophoresis Enrichment of CD34 Cells from Peripheral Blood Stem Cell Harvests,” Bone Marrow Transplantation, vol. 18, pp. 777-782, 1996. |
| Marszalek et al; “Determination of Electric Parameters of Cell Membranes by a Dielectrophoresis Method,” Biophysical Journal, vol. 59, pp. 982-987, May 1991. |
| Mascia et al; “Temporal Relationship Between Endothelin-1 Concentrations and Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage-Editorial Comment Endothelin-1 in Vasospasm After SAH,” Stroke, pp. 1185-1190, May 2001. |
| McCulloch et al; “A radical approach to stroke therapy,” PNAS, vol. 98, No. 20, pp. 10989-10991, Sep. 25, 2001. |
| McKeating et al; “Cytokines and Adhesion in Acute Brain Injury,” British Journal of Anaesthesia, vol. 80, pp. 77-84, 1998. |
| McKhann et al; “Plasmapherisis and Guillan-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis,” Annals of Neurology, vol. 23, pp. 347-353, No. 4, Apr. 1988. |
| Melnikova, “Therapies for Alzheimer's disease”, Nature Reviews, vol. 6, pp. 341-342, May 2007. |
| Misaki et al; “Contrast-Enhanced Fluid-Attenuated Inversion Recovery MRI is Useful to Detect the CSF Dissemination of Glioblastoma,” Journal of Computer Assisted Tomography, vol. 25, No. 6, pp. 953-956, 2001. |
| Monsonego et al; “Immunotherapeutic Approaches to Alzheimer's Disease,” Science, vol. 302, pp. 834-838, Oct. 31, 2003. |
| Morgan et al; “A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,” Nature, vol. 408, pp. 982-985, Dec. 2000. |
| Morganti-Kossman et al; “Production of Cytokines Following Brain Injury : Beneficial and Deleterious for the Damaged Tissue,” Molecular Psychiatry, vol. 2, pp. 133-136, 1997. |
| Nicoll et al; “Abeta species removal after abeta42 immunization,” Journal of Neuropathology Exp. Neurol; vol. 65, No. 11, pp. 1040-1048, Nov. 2006. |
| Noseworthy, “Progress in determining the causes and treatment of multiple sclerosis,” vol. 399, pp. A40-A47, Supp. Jun. 24, 1999. |
| Onda et al; “Cerebral Glioblastoma with Cerebrospinal Fluid Dissemination: A Clinicopathological Study of 14 Cases Examined by Complete Autopsy,” Neurosurgery, vol. 25, No. 4 pp. 1040-1048, 1989. |
| Orgogozo et al; “Subacute meningoencephalitis in a subset of patients with AD after Aβ immunization,” Neurology, vol. 61, pp. 46-54, Jul. 2003. |
| Park, et al., “3-D Electrode Designs for Flow-through Dielectrophoretic Systems”, Electrophoresis, 26(19): 3745-3757, Oct. 2005. |
| Parkhill et al; “The genome sequence of the food-bome pathogen Campylobacter jejuni reveals hypervariable sequences,” Nature, vol. 403, pp. 665-668, Feb. 10, 2000. |
| Perfect, “Cryptococcous Neoformans: The Yeast that Likes it Hot,” FEMS Yeast Res; vol. 6, pp. 463-468, 2006. |
| Pethig et al; “Applicants of Dielectrophoresis in Biotechnology,” Tibtech, vol. 15, pp. 426-432, Oct. 1997. |
| Pethig, “Dielectrophoresis: Status of the Theory, Technology and Applications,” Biomicrofluidics, vol. 4, pp. 022811-1-35, 2010. |
| Pethig, “Dielectrophoresis: Using Inhomogeneous AC Electrical Fields to Separate and Manipulate Cells,” Critical Reviews in Biotechnology, vol. 16, No. 4, pp. 331-348, 1996. |
| Polderman et al; “Therapeutic Hypothermia and Controlled Normothermia in the Intensive Care Unit: Practical Considerations, Side Effects, and Cooling Methods,” Crit. Care Med; vol. 37, No. 3 Abstract (1 page), pp. 1101-1120, Mar. 2009. |
| Reiber, “Proteins in cerebrospinal fluid and blood: Barriers, CSF flow rate and source-related dynamics”, REIBER, Restorative Neurology and Neuroscience, vol. 21, pp. 79-96, 2003. |
| Roberson et al; “100 Years and Counting: Prospects for Defeating Alzheimer's Disease,” Science, vol. 314, pp. 781-784, Nov. 3, 2006. |
| Rowland, “Amyotrophic Lateral Sclerosis: Human Challenge for Neuroscience,” Proc. Natl. Acad. Sci; vol. 92, pp. 1251-1253, Feb. 1995. |
| Shoulson, “Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs,” Science, vol. 282, pp. 1072-1074, Nov. 6, 1998. |
| Steece-Collier et al; “Etiology of Parkinson's disease: Genetics and environment revisited,” PNAS, vol. 99, No. 22, pp. 13972-13974, Oct. 29, 2002. |
| Tay et al; “Electrical and Thermal Characterization of a Dielectrophoretic chip with 3D Electrodes for Cells Manipulation,” Electrochimica. Acta; vol. 52, pp. 2862-2868, 2007. |
| Taylor et al; “Toxic Proteins in Neurodegenerative Disease”, Science, vol. 296, pp. 1991-1995, Jun. 14, 2002. |
| “External CSF Drainage,” Aqueduct Neurosciences, 2 pages, Jul. 2014. |
| “Therapeutic Hypothermia for Spinal Cord Injury,” Crit. Care Med. vol. 37, Supp. 7, Abstract (1 page) pp. S238-S242, Jul. 2009. |
| World Journal Of Radiology, Journal of Radiology, vol. 4. No. 6, pp. 241-290, Jun. 28, 2012. |
| Valentine, et al; “Misfolded CuZnSOD and amyotrophic lateral sclerosis,” PNAS, vol. 100, No. 7, pp. 3617-3622, Apr. 1, 2003. |
| Vernino et al; “Autoimmune encephalopathies,” The Neurologist, vol. 13, No. 3, pp. 140-147, May 2007. |
| Voldman, “Electrical Forces for Microscale Cell Manipulation,” Annu. Rev. Biomed. Eng. vol. 8, pp. 425-454, 2006. |
| Weis et al; “Noninvasive Monitoring of Brain Temperature During Mild Hypothermia,” Magn. Reson. Imaging, vol. 27, No. 7, Abstract (1 page), pp. 923-932, Sep. 2009. |
| Wollinsky et al; “CSF filtration is an effective treatment of Guillain-Barre syndrome: A randomized clinical trial,” Neurology, vol. 57, pp. 774-780, Sep. 2001. |
| Yuki et al; “Carbohydrate mimicry between human ganglioside GM1 and Campylobacter Jejuni lipooligosaccharide causes Guillain-Barré syndrome,” PNAS, vol. 101, No. 31, pp. 11404-11409, Aug. 3, 2004. |
| Ziebell et al; “Involvement of Pro- and Anti-Inflammatory Cytokines and Chemokines in the Pathophysiology of Traumatic Brain Injury,” Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics, vol. 7, pp. 22-30, Jan. 2010. |
| European Office Action for European Patent No. 07873762.4 , dated Dec. 7, 2016 (5 pages). |
| Mahon et al; “North American Clinical Experience with the EKOS MicroLysUS Infusion Catheter for the Treatment of Embolic Stroke,” AJNR Am j. Neuroradiology, vol. 24, pp. 534-538. |
| Rogers et al; “Precutaneous aspiration of brain tumor cysts via the Ommaya reservoir system,” Neurology, vol. 41, pp. 279-282. |
| Siddiqui et al; “Use of the Penumbra System 054 plus Low Dose Thrombolytic Infusion for Mulitfocal Venous Sinus Thrombosis,” Interventional Neuroradiology, vol. 18, pp. 314-319, 2012. |
| Spielberg, GmbH & Co. KG, “EVD—Catheters,” downloaded on Nov. 3, 2016 from website. http://www.spielberg.de/products/drainage/silverline_evd_catheter_3001002.html (1 page). |
| Wagner et al; “Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemmorrgage: edema reduction and blood-brain barrier protection,” J. Neurosurg; vol. 90, pp. 491-498, Mar. 1999. |
| Ziu et al; “A Series of Cerebral Venous Sinus Thromboses Treated with Intra-Arterial tPA infused over Ten Hours with a 0.027-inch Catheter and Literature Review,” pp. 1-13, Jun. 23, 2016. |
| International Search Report for International Patent Application No. PCT/US2016/064721, dated Feb. 17, 2017 (3 pages). |
| International Search Report for International Patent Application No. PCT/US2016/055724, dated Feb. 15, 2017 (7 pages). |
| Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2016/064721, dated Feb. 17, 2017 (7 pages). |
| Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2016/055724, dated Feb. 15, 2017 (11 pages). |
| Firer, “Efficient elution of functional proteins in affinity chromatography,” J. Biochem. Biophys. Methods 49, pp. 433-442, 2001. |
| Park et al; “Continuous Dielectrophoretic Bacterial Separation and Concentration from Physiological Media of High Conductivity,” The Royal Society of Chemistry, Lab Chip, vol. 11, pp. 2893-2900, 2011. |
| Japanese Rejection of Appeal for related Japanese patent application No. 2009-531646, dated Jan. 25, 2016 (13 pages). |
| European Search Report and Opinion for European Patent Application No. 07873762.4, dated May 27, 2011 (11 pages). |
| International Search Report and Written Opinion of the International Searching Authority for International Patent Application for International Patent Application No. PCT/US2016/036626, dated Sep. 8, 2016. |
| International Search Report and Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2010/01186, dated Jun. 21, 2010 (7 pages). |
| International Search Report and Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2007/80834, dated Oct. 28, 2008 (8 pages). |
| Arnold et al; Electro-Rotation: Develpoment of a Technique for Dielectric Measurements on Individual Cells and Particles, Journal of Electrostatics, vol. 21, pp. 151-191, 1988. |
| Arvin et al; “The Role of Inflammation and Cytokines in Brain Injury,” Neuroscience and Biobehavorial Reviews, vol. 20, No. 3, pp. 445-452, 1996. |
| Banci et al; “Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: A possible general mechanism for familial ALS,” PNAS, vol. 104, No. 27, pp. 11263-11267, Jul. 3, 2007. |
| Bayer et al; “Evaluation of the safety and immunogenicity of synthetic AB42 (AN1792) in patients with AD,” Neurology, vol. 64, pp. 94-101, Jan. 2005. |
| Becker et al; “Separation of Human Breast Cancer Cells from Blood by Differential Dielectric Affinity,” Proc. Natl. Acad. Sci, vol. 92, pp. 860-864, Jan. 1995. |
| Becker et al; “The Removal of Human Leukemia Cells for Blood Using Interdigitated Microelectrodes,” J. Phys.D: Appl. Phys; vol. 27, pp. 2659-2662, 1994. |
| Blennow et al; “Alzheimer's disease,” Lancet, vol. 368, pp. 387-103, Jul. 29, 2006. |
| Buzzigoli et al; “Plasmapherisis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobin,” Anaesth Intensive Care, vol. 38, No. 2, pp. 387-389, Mar. 2010. |
| Cambria et al; “Clinical Experience with Epidural Cooling for Spinal Cord Protection during Thoracic and Thoracoabdominal Aneurysm Repair,” Journal of Vascular Surgery, vol. 25, No. 2, pp. 234-243, Feb. 1997. |
| Caughey et al; “Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders,” Annu. Rev. Neurosci; vol. 26, pp. 267-298, 2003. |
| Cook, “Combined Spinal-Epidural Techniques,” Anaesthesia, vol. 55, pp. 42-64, 2000. |
| Covaciu et al; “Brain Temperature in Volunteers Subjected to Intranasal Cooling,” Intensive Care Med; vol. 37, No. 8,Abstract (1 page), Aug. 2011. |
| Dawson et al; “Molecular Pathways of Neurodegeneration in Parkinson's Disease,” Science, vol. 32, pp. 819-822, Oct. 21, 2003. |
| Dekosky et al; “Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders,” vol. 302, pp. 830-834, Oct. 31, 2003. |
| Delhaas, “Extradural and Subarachnoid Catheterization Using the Seidinger Technique,” British Journal of Anaesthesia, vol. 76, pp. 149-150, 1996. |
| Dias-Santagata et al; “Oxidative stress mediates tau-induced neurodegeneration in Drosophila,” Journal of Clinical Investigation, vol. 117, pp. 236-245, Jan. 2007. |
| Dunnett et al; Prospects for new restorative and neuroprotective treatments in Parkinson's disease, Nature, vol. 399, pp. A32-A38, SUPP, Jun. 24, 1999. |
| Elefteriades, et al; “Litigation in Nontraumatic Aortic Diseases—A Tempest in the Malpractice Maelstrom,” Cardiology vol. 109, pp. 263-272, 2008. |
| Enchev et al; “Historical Trends of Neuroendoscopic Surgical Techniques in the Treatment of Hydrocephalus,” Neurosurgery Review, vol. 31, pp. 249-262, 2008. |
| Gascoyne et al.; Dielectrophoretic Separation of Cancer Cells from Blood IEEE Transactions of Industry Applications, vol. 33, No. 3, pp. 670-678, May/Jun. 1997. |
| Gascoyne et al; “Isolation of Rare Cells from Cell Mixtures by Dielectrophoresis,” Electrophoresis, vol. 30, No. 8, pp. 1388-1398, Apr. 2009. |
| Gascoyne et al.; “Particle Separation by Dielectrophoresis,” Electrophoresis, vol. 23, No. 13, pp. 1973-1983, Jul. 2002. |
| Gilman et al; “Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, pp. 1553-1562, vol. 64, May 2005. |
| Glabe, “Common mechanisms of amyloid oligomer pathogenisis in degenerative disease,” Neurobiology of Aging, pp. 570-575, vol. 27, 2006. |
| Haltiwanger, “The Electrical Properties of Cancer Cells,” www.royalrife.com/haltiwanger1 (62 pages), Jul. 2010. |
| Han et al; “An Electrorotation Technique for Measuring the Dielectric Properties of Cells with Simultaneous Use of Negative Quadropolar Dielectrophoresis and Electrorotation,” The Royal Society of Chemistry, Analyst, pp. 1529-1537, vol. 138, Mar. 2006. |
| Hansson et al; Association between CDF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol; pp. 228-234, vol. 5, Mar. 2006. |
| Helmy et al; “The Cytokine Response to Human Traumatic Brain Injury: Temporal Profiles for Cerebral Parenchymal Production,” Journal of Cerebral Blood Flow & Metabolism, pp. 658-670, vol. 31, 2011. |
| Hock et al; Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease, pp. 547-554, vol. 38, May 22, 2003. |
| Hohfeld, et al; “Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) piplelines,” PNAS, pp. 14599-14606, vol. 101, Suppl. 2, Oct. 5, 2004. |
| Huang et al; Electrode Design for Negative Dielectrophoresis, Measurement Science and Technology, pp. 1142-1146, vol. 2, Dec. 1991. |
| Janus et al; “A beta peptide immunization reduces behavorial impairment and plaques in a model of Alzheimer's disease in a model of Alzheimer's disease,” Nature, pp. 979-982, vol. 408, Dec. 2000. |
| Jones et al; “Multipolar Dielectrophoretic and Electrorotation Theory,” Journal of Electrostatics, pp. 121-134, vol. 37, 1996. |
| Kessler et al; “Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage,” Surgical Neurology, pp. S1:2-S1:5, vol. 64, 2005. |
| Koo et al; “Amyloid diseases: Abnormal protein aggregation in neurodegeneration,” Proc. Natl. Acad. Sci; pp. 9989-9990, vol. 96, Aug. 1999. |
| Kuwabara et al; “Intravenous immunoglobulin therapy for Guillain-Barre syndrome with IgG anti-GM1 antibody,” Miscle & Nerve, Jan. 2001, pp. 53-58, Jan. 2001. |
| Lau et al; “Tau Protein Phosphorylation as a Therapeutic Target in Alzheimer's Disease,” Current Topics in Medicinal Chemistry, pp. 395-415, vol. 2, 2002. |
| Levi et al; “Clinical Application of Modest Hypothermia After Spinal Cord Injury,” J. Neurotrauma, pp. 407-415, vol. 26, No. 3, Abstract (1 page), Mar. 2009. |
| Li et al; “Continuous Dielectrophoretic Cell Separation Microfluidic Device,” The Royal Society of Chemistry, Lab Chip, pp. 239-248, vol. 7, 2007. |
| “LiquoGuard”, Moller Medical, Brochure, 2 pages, published on or before 2015. |
| MacDonald et al; “Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution,” Nature Clinical Practice, Neurology, pp. 256-263, vol. 3, No. 5, May 2007. |
| Madeira-Lopes et al; Comparative Study of the Temperature Profiles of Growth and Death of the Pathogenic Yeast Cryptococcus Neoformans and the non-pathogenic Cryptococcus Albidus, Journal of Basic Microbiology, pp. 43-47, vol. 26, 1986. |
| Markx et al; “Dielectrophoretic Separation of Bacteria Using a Conductivity Gradient,” Journal of Biotechnology, pp. 175-180, vol. 51, Dec. 1996. |
| Markx et al; “Dielectrophoretic Separation of Cells: Continuous Separation,” Biotechnology and Bioengineering, pp. 337-343, vol. 45, No. 4, Feb. 1995. |
| Number | Date | Country | |
|---|---|---|---|
| 20200147357 A1 | May 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62263305 | Dec 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15367592 | Dec 2016 | US |
| Child | 16742870 | US |
